Oséo backs Cerenis and Novasep with €10.7m

The funding will finance the development of CER-001, designed to treat atherosclerotic cardiovascular disease. Cerenis and Novasep have collaborated on the development of CER-001 since 2007; Cerenis will develop the drug, while Novasep will be responsible for the global manufacturing of clinical and initial commercial supplies.

Cerenis Therapeutics is a pharmaceutical company focused on the discovery, development and commercialization of HDL therapies for the treatment of cardiovascular and metabolic diseases. Novasep develops, markets and operates production technologies for the life sciences sector.

The unquote" team is currently researching this transaction. In-depth deal information for subscribers will follow shortly.

If you have any information regarding this transaction, please contact Grégoire Gille on +44 20 7484 9824 or gregoire.gille@incisivemedia.com

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• France
• Benelux
• UK / Ireland
• Nordics
• DACH
• Southern Europe
• CEE
• Early-stage
• Healthcare
• France